Tuesday, October 20, 2026 Never miss a recall or a rule change Get the free brief →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
RegulatorySisram's Profhilo clears China regulatory hurdletodayBusiness & M&AAbbVie takes $216M charge on Q3 deals, cuts earnings2 weeks agoBusiness & M&ASteel Partners sets October 30 deadline on $16.75 InMode bidtodayBusiness & M&AHugel chases 1 trillion won in three yearslast weekDevices & TechAesthetic Management Partners launches Exo-ME skin booster2 days agoDevices & TechKorean toxin makers split as Daewoong and Hugel advancelast weekBusiness & M&ASkinHealth Systems executes 1-for-20 reverse split3 days agoBusiness & M&AHenry Schein names ITT CFO Emmanuel Caprais as new finance chieflast weekBusiness & M&AGalderma buys ZO Skin Health for $1.5 billion3 days agoDevices & TechDaewoong targets 2027 for semaglutide patch factory5 days agoDevices & TechEltaMD launches post-procedure recovery system4 days agoBusiness & M&ASisram Medical to repurchase up to 1% of shares4 days ago
Business & M&A

Steel Partners sets October 30 deadline on $16.75 InMode bid

The activist investor says InMode's board has refused to engage in good faith and breached fiduciary duties by conditioning diligence on dismissal of shareholder claims.

Close-up of two businessmen shaking hands, symbolizing agreement and partnership.
Photo: Bia Limova / Pexels
1-YEAR MOVE
+3% −14%
INMD ▲1.0%
1-year price move by ticker
TickerCompany1-year change
INMDInMode Ltd.+1.0%

Get the free Inside MedSpa brief by email

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Steel Partners Holdings L.P., a major shareholder of InMode Ltd. (NASDAQ: INMD), sent an open letter to stakeholders on October 19, 2026, setting an October 30, 2026 deadline for its all-cash offer to buy the company at $16.75 per share. The letter appeared on Yahoo Finance.

Steel first proposed buying InMode on July 9, 2026. More than three months later, the company still has not signed a non-disclosure agreement, opened a data room, or shared materials for due diligence, according to the letter signed by Steel's Executive Chairman Warren G. Lichtenstein. The board's Special Committee refuses to proceed unless Steel drops its claims against the directors individually.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Steel says the board's Special Committee has refused to move forward without Steel dismissing its claims against the directors individually.

Steel views this as a breach of fiduciary duty. The activist investor argues that conditioning access to basic information on surrendering shareholder rights—specifically the ability to hold the board accountable—contradicts the board's stated commitment to "the highest standards of corporate governance, transparency, and objectivity. Steel says it has repeatedly offered to pause litigation during talks and has been ready to sign a standard non-disclosure agreement since July.

The timing matters. On September 16, InMode disclosed that a competing proposal from Chief Executive Officer Moshe Mizrahy's group had expired without closing. Steel's offer is now the only bid on the table.

Steel's letter attacks the board's independence. The activist points to overlapping board service between directors and Mizrahy at other companies, deals between InMode and companies whose directors approved them, and a proposed buyer group led by Mizrahy that included InMode's own manufacturer and its United Kingdom distributor. Steel contends the board lacks the independence required to evaluate competing proposals fairly or to challenge the CEO.

InMode's operating performance has deteriorated. The company reported second-quarter results on August 5. Revenue was $95.6 million, flat year-over-year, with gross margin declining to 75% from 80% and non-GAAP operating margin falling to 17% from 28%. Management lowered full-year non-GAAP operating income projections to between $68 million and $73 million—the sixth time the company has cut earnings projections since February 2024. The company told shareholders it expects these trends to continue.

Steel also notes that InMode has suspended earnings calls and cut back investor communication. After a failed strategic review, an expired insider proposal, and continued operating uncertainty, the activist says shareholders have received no evidence of a credible plan under current leadership.

Steel's letter signals what comes next. If the board does not engage meaningfully before the October 30 deadline, Steel says it will pursue all available remedies to hold the board accountable and replace directors with ones shareholders choose. The activist frames this as a matter of protecting shareholder interests against what it characterizes as a board that has breached its duties of loyalty and care by failing to supervise a CEO whose conduct has raised serious questions under U.S. securities laws.

The board's response to Steel's ultimatum remains to be seen. The company has not asked Steel a single question about the details of its offer and has told shareholders nothing about it, according to the letter.

Business information, not medical or legal advice. Verify regulatory status at FDA.gov.

Source: original report ↗

Business information, not medical or legal advice. Verify product status at FDA.gov.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Share

https://insidemedspa.com/article/steel-partners-october-30-inmode-deadline/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Inside MedSpa · Free brief

    By the time it's news, it's too late.

    FDA decisions, recalls and the rules you operate under, drafted from the source documents and sent free by email.

    Get the free brief The free Inside MedSpa brief · no card · unsubscribe anytime.
    FDA, recalls and rule changes for practice owners Get the free brief →